Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial (thelancet.com)
New—Once-weekly #IcoSema versus once-daily insulin glargine U100 in type 2 #diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial thelancet.com/journals/lan...